Oncolytic Adenovirus: Prospects for Cancer Immunotherapy.
cancer vaccine
genomic modification
immune checkpoint inhibitor
immunotherapy
oncolytic adenovirus
Journal
Frontiers in microbiology
ISSN: 1664-302X
Titre abrégé: Front Microbiol
Pays: Switzerland
ID NLM: 101548977
Informations de publication
Date de publication:
2021
2021
Historique:
received:
09
05
2021
accepted:
21
06
2021
entrez:
9
8
2021
pubmed:
10
8
2021
medline:
10
8
2021
Statut:
epublish
Résumé
Immunotherapy has moved to the forefront of modern oncologic treatment in the past few decades. Various forms of immunotherapy currently are emerging, including oncolytic viruses. In this therapy, viruses are engineered to selectively propagate in tumor cells and reduce toxicity for non-neoplastic tissues. Adenovirus is one of the most frequently employed oncolytic viruses because of its capacity in tumor cell lysis and immune response stimulation. Upregulation of immunostimulatory signals induced by oncolytic adenoviruses (OAds) might significantly remove local immune suppression and amplify antitumor immune responses. Existing genetic engineering technology allows us to design OAds with increasingly better tumor tropism, selectivity, and antitumor efficacy. Several promising strategies to modify the genome of OAds have been applied: capsid modifications, small deletions in the pivotal viral genes, insertion of tumor-specific promoters, and addition of immunostimulatory transgenes. OAds armed with tumor-associated antigen (TAA) transgenes as cancer vaccines provide additional therapeutic strategies to trigger tumor-specific immunity. Furthermore, the combination of OAds and immune checkpoint inhibitors (ICIs) increases clinical benefit as evidence shown in completed and ongoing clinical trials, especially in the combination of OAds with antiprogrammed death 1/programed death ligand 1 (PD-1/PD-L1) therapy. Despite remarkable antitumor potency, oncolytic adenovirus immunotherapy is confronted with tough challenges such as antiviral immune response and obstruction of tumor microenvironment (TME). In this review, we focus on genomic modification strategies of oncolytic adenoviruses and applications of OAds in cancer immunotherapy.
Identifiants
pubmed: 34367111
doi: 10.3389/fmicb.2021.707290
pmc: PMC8334181
doi:
Types de publication
Journal Article
Review
Langues
eng
Pagination
707290Informations de copyright
Copyright © 2021 Zhao, Liu, Li, Wu, Zhang, Zhang, Lei and Xu.
Déclaration de conflit d'intérêts
The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Références
J Immunol. 2014 Jun 15;192(12):5451-8
pubmed: 24907378
J Med Virol. 2012 Sep;84(9):1408-14
pubmed: 22825819
Cytokine Growth Factor Rev. 2014 Aug;25(4):377-90
pubmed: 25200249
Front Immunol. 2020 Oct 15;11:575597
pubmed: 33178203
Front Immunol. 2018 May 22;9:1104
pubmed: 29872437
Nat Commun. 2017 Nov 9;8(1):1395
pubmed: 29123084
J Clin Oncol. 2015 Sep 1;33(25):2780-8
pubmed: 26014293
Clin Cancer Res. 2013 May 15;19(10):2734-44
pubmed: 23493351
Nat Commun. 2019 Dec 17;10(1):5747
pubmed: 31848338
Cancer Immunol Immunother. 2015 Aug;64(8):977-87
pubmed: 25956394
Oncoimmunology. 2018 Oct 29;8(2):e1532763
pubmed: 30713786
Tumour Biol. 2014 Oct;35(10):9447-57
pubmed: 25117071
Cancer Res. 1997 Oct 15;57(20):4570-7
pubmed: 9377571
Cell Stem Cell. 2014 Mar 6;14(3):342-56
pubmed: 24607406
Cancers (Basel). 2020 May 02;12(5):
pubmed: 32370135
Ann Surg Oncol. 2019 Dec;26(13):4633-4641
pubmed: 31414290
Mol Ther. 2012 Sep;20(9):1821-30
pubmed: 22871667
Cancer Sci. 2017 May;108(5):831-837
pubmed: 28266780
Mol Ther Oncolytics. 2016 Dec 31;4:77-86
pubmed: 28345026
Blood. 1997 Oct 1;90(7):2541-8
pubmed: 9326219
Mol Ther. 2004 Jun;9(6):786-803
pubmed: 15194046
J Virol. 2017 May 26;91(12):
pubmed: 28381574
N Engl J Med. 2010 Aug 19;363(8):711-23
pubmed: 20525992
Oncotarget. 2015 Feb 28;6(6):4467-81
pubmed: 25714011
PLoS One. 2016 Jan 25;11(1):e0147211
pubmed: 26808201
Oncoimmunology. 2015 Aug 12;5(2):e1074377
pubmed: 27057442
J Natl Cancer Inst. 2003 May 7;95(9):652-60
pubmed: 12734316
Cancer Gene Ther. 2020 Dec;27(12):948-959
pubmed: 32355275
Nat Med. 2013 Mar;19(3):329-36
pubmed: 23396206
Hum Vaccin Immunother. 2017 Nov 2;13(11):2561-2574
pubmed: 28857666
J Urol. 2012 Dec;188(6):2391-7
pubmed: 23088985
Int J Biol Sci. 2019 Sep 7;15(12):2548-2560
pubmed: 31754328
Proc Natl Acad Sci U S A. 2010 Dec 14;107(50):21248-55
pubmed: 21081700
Int J Cancer. 2001 Dec 15;94(6):842-9
pubmed: 11745487
J Cell Biochem. 2019 Jun;120(6):8815-8828
pubmed: 30536960
Oncologist. 2020 Jun;25(6):479-e899
pubmed: 31594913
Nat Commun. 2020 Jun 24;11(1):3187
pubmed: 32581235
J Gastroenterol. 2013 Jul;48(7):798-808
pubmed: 23188090
Clin Rev Allergy Immunol. 2016 Jun;50(3):312-32
pubmed: 26215166
Cancer Gene Ther. 2008 May;15(5):315-22
pubmed: 18274558
Gene Ther. 2012 Oct;19(10):988-98
pubmed: 22071969
Hum Gene Ther. 2016 Apr;27(4):325-37
pubmed: 26993072
Oncolytic Virother. 2018 Nov 26;7:117-128
pubmed: 30538968
Nat Biotechnol. 2003 Nov;21(11):1328-35
pubmed: 14555956
CA Cancer J Clin. 2021 May;71(3):209-249
pubmed: 33538338
Sci Transl Med. 2019 Aug 14;11(505):
pubmed: 31413142
Nat Rev Clin Oncol. 2019 Mar;16(3):151-167
pubmed: 30523282
Cancer. 2020 Jul 15;126(14):3192-3201
pubmed: 32401342
Virology. 2009 Sep 30;392(2):222-9
pubmed: 19682720
Int Rev Immunol. 2014 Jan;33(1):45-53
pubmed: 24127823
Mol Ther. 2020 May 6;28(5):1251-1262
pubmed: 32145203
Eur J Immunol. 1994 Sep;24(9):2219-27
pubmed: 8088337
Semin Cancer Biol. 2020 Oct;65:51-64
pubmed: 31874279
Immunity. 2020 Jan 14;52(1):17-35
pubmed: 31940268
Clin Cancer Res. 2021 Mar 15;27(6):1807-1820
pubmed: 33376098
Nat Commun. 2019 Feb 14;10(1):741
pubmed: 30765704
Cancer Gene Ther. 2021 May;28(5):442-454
pubmed: 32920593
Nat Commun. 2019 May 28;10(1):2235
pubmed: 31138805
Clin Microbiol Rev. 2014 Jul;27(3):441-62
pubmed: 24982316
Hum Gene Ther. 2015 Mar;26(3):134-44
pubmed: 25557131
Mol Cell Biol. 2019 Jul 29;39(16):
pubmed: 31138663
Trends Pharmacol Sci. 2012 Aug;33(8):442-8
pubmed: 22621975
Blood. 2018 Jan 4;131(1):49-57
pubmed: 29118009
Mol Ther. 2016 Aug;24(7):1323-32
pubmed: 27039846
Curr Med Chem. 2019;26(17):3009-3025
pubmed: 28782469
Oncoimmunology. 2018 Mar 13;7(8):e1442169
pubmed: 30221036
Nat Med. 2011 Jan;17(1):96-104
pubmed: 21151137
Nat Commun. 2019 Jul 19;10(1):3236
pubmed: 31324774
Cancers (Basel). 2019 Feb 08;11(2):
pubmed: 30744019
Hum Gene Ther. 2014 Apr;25(4):301-17
pubmed: 24580050
Biomaterials. 2011 Dec;32(35):9536-45
pubmed: 21959008
Clin Cancer Res. 2006 Jan 1;12(1):305-13
pubmed: 16397056
Hum Gene Ther. 2004 Nov;15(11):1022-33
pubmed: 15610603
Nat Commun. 2018 Nov 8;9(1):4679
pubmed: 30410017
Prog Retin Eye Res. 2020 May;76:100826
pubmed: 31891773
Cancer Immunol Immunother. 2013 Aug;62(8):1293-301
pubmed: 23624851
Int J Cancer. 2012 Apr 15;130(8):1937-47
pubmed: 21630267
Mol Cancer Ther. 2017 Apr;16(4):662-670
pubmed: 28138026
Oncoimmunology. 2020 Feb 24;9(1):1729300
pubmed: 32158622
J Virol. 1998 Aug;72(8):6875-9
pubmed: 9658137
Mol Ther. 2020 Mar 4;28(3):794-804
pubmed: 31991110
Curr Opin Immunol. 2018 Apr;51:111-122
pubmed: 29554495
Cancer Res. 2017 Apr 15;77(8):2040-2051
pubmed: 28235763
Science. 1996 Oct 18;274(5286):373-6
pubmed: 8832876
J Hematol Oncol. 2019 Nov 28;12(1):126
pubmed: 31779642
Clin Cancer Res. 2009 Dec 1;15(23):7375-80
pubmed: 19920098
Cancer Gene Ther. 2010 Jul;17(7):484-91
pubmed: 20168351
Cancer Res. 2016 Nov 15;76(22):6747-6759
pubmed: 27680683
Nat Med. 2000 Oct;6(10):1134-9
pubmed: 11017145
Trends Immunol. 2018 Mar;39(3):209-221
pubmed: 29275092
Urol Oncol. 2018 Oct;36(10):440-447
pubmed: 28755959
Int J Cancer. 2015 Nov 1;137(9):2253-69
pubmed: 25944623
FEBS Lett. 2019 Dec;593(24):3583-3608
pubmed: 31769017
Curr Opin Infect Dis. 2018 Jun;31(3):251-256
pubmed: 29601326
Oncotarget. 2015 Oct 13;6(31):31344-59
pubmed: 26374823
Sci Transl Med. 2019 Jan 30;11(477):
pubmed: 30700577
Oncoimmunology. 2018 Apr 9;7(5):e1412902
pubmed: 29721366
Clin Cancer Res. 2017 Oct 1;23(19):5846-5857
pubmed: 28536305
Front Oncol. 2020 Sep 09;10:1786
pubmed: 33014876
Am J Cancer Res. 2020 Mar 01;10(3):727-742
pubmed: 32266087
Vaccine. 2009 Jun 24;27(31):4225-39
pubmed: 19481312
Nat Rev Immunol. 2015 Aug;15(8):486-99
pubmed: 26205583
Eur J Immunol. 1993 Oct;23(10):2631-41
pubmed: 8405064
Hum Gene Ther. 2021 Feb;32(3-4):192-202
pubmed: 33050725
J Hematol Oncol. 2019 Aug 22;12(1):84
pubmed: 31438991
Cancer Lett. 2011 Aug 1;307(1):93-103
pubmed: 21504839
Cancer Lett. 2002 Jun 6;180(1):23-32
pubmed: 11911966
Semin Immunopathol. 2019 Jan;41(1):69-85
pubmed: 29978248
Mol Ther. 2017 Nov 1;25(11):2440-2451
pubmed: 28974431
Int J Mol Sci. 2018 Sep 10;19(9):
pubmed: 30201920
Sci Transl Med. 2018 Jan 3;10(422):
pubmed: 29298869
Sci Rep. 2018 Jan 23;8(1):1420
pubmed: 29362367
Cancers (Basel). 2019 May 15;11(5):
pubmed: 31096717
Clin Cancer Res. 2019 Nov 15;25(22):6801-6814
pubmed: 31455679
Mol Cancer Ther. 2008 Jun;7(6):1598-603
pubmed: 18566230
Nat Rev Clin Oncol. 2010 Nov;7(11):653-64
pubmed: 20838415
Gene Ther. 2015 Apr;22(4):305-15
pubmed: 25588741
Clin Cancer Res. 2020 Jan 1;26(1):71-81
pubmed: 31694832
Nat Rev Cancer. 2012 Mar 22;12(4):252-64
pubmed: 22437870
Sci Rep. 2016 Jun 07;6:27598
pubmed: 27273616
Cancer Res. 2017 Jul 15;77(14):3894-3907
pubmed: 28566332
Oncologist. 2019 Feb;24(Suppl 1):S31-S41
pubmed: 30819829
J Clin Oncol. 2018 May 10;36(14):1419-1427
pubmed: 29432077
Curr Opin Biotechnol. 2007 Dec;18(6):546-56
pubmed: 18063357
J Immunother Cancer. 2016 Mar 15;4:17
pubmed: 26981247
Cancer Gene Ther. 2018 Jun;25(5-6):106-116
pubmed: 29755109
J Hematol Oncol. 2017 Feb 21;10(1):53
pubmed: 28222796
Nat Rev Cancer. 2019 Jun;19(6):326-338
pubmed: 31053804
JAMA Oncol. 2018 Mar 1;4(3):315-316
pubmed: 29270625
J Immunother Cancer. 2019 Jan 28;7(1):20
pubmed: 30691536
Cancer Cell. 2017 Jun 12;31(6):848-848.e1
pubmed: 28609660
Mol Ther. 2018 Sep 5;26(9):2243-2254
pubmed: 30017877
Int J Mol Sci. 2020 Apr 01;21(7):
pubmed: 32244804
Gene Ther. 2017 Feb;24(2):92-103
pubmed: 27906162
Oncoimmunology. 2018 Sep 19;8(1):e1512329
pubmed: 30546947
Cancer Res. 2000 Oct 1;60(19):5420-6
pubmed: 11034083
Nature. 2015 Jul 9;523(7559):231-5
pubmed: 25970248
Mol Ther Methods Clin Dev. 2020 Jun 18;18:376-389
pubmed: 32695840
Int J Cancer. 2015 Oct 1;137(7):1775-83
pubmed: 25821063
Mol Ther. 2006 Aug;14(2):164-74
pubmed: 16580264
Cytokine Growth Factor Rev. 2002 Apr;13(2):155-68
pubmed: 11900991
Cancer Metastasis Rev. 2019 Sep;38(3):333-346
pubmed: 31659564
Cancer Gene Ther. 2009 Dec;16(12):883-91
pubmed: 19444303
J Immunother Cancer. 2020 Jan;8(1):
pubmed: 31940588
CA Cancer J Clin. 2020 Mar;70(2):86-104
pubmed: 31944278
J Immunol. 2011 Aug 1;187(3):1254-63
pubmed: 21705618
J Immunother Cancer. 2021 Mar;9(3):
pubmed: 33762322
Exp Mol Med. 2016 Jul 01;48(7):e242
pubmed: 27364892
Mol Cancer Ther. 2020 Mar;19(3):966-971
pubmed: 31907220
Nat Rev Drug Discov. 2015 Mar;14(3):183-202
pubmed: 25698643
Sci Transl Med. 2019 Jan 23;11(476):
pubmed: 30674657
Science. 2015 Apr 3;348(6230):56-61
pubmed: 25838373